Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

APRIL 2, 2022

Bienstar Plans To Build LATAM’s First Network of Integrative Mental Health Clinics. TORONTO, ON / ACCESSWIRE / March 31, 2022 / Novamind Inc. a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil (the “Ibogaine Group”).

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

FEBRUARY 9, 2022

09, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients.

Research and Development 52

Research and Development Clinical Trials Treatment Patients 52

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). May 11, 2022 02:00 AM Eastern Daylight Time. Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). About MAPS Public Benefit Corporation (MAPS PBC). Executive Summary.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Very few studies have also been done examining cannabis for the treatment of sleep disorders. This report from Vice on the back of new research released by the University of Sydney.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

JUNE 9, 2022

We understand the number of people who will need medical treatment due to this exposure. The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. ARV (revised).

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

FEBRUARY 28, 2022

20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Essay by I. Glenn Cohen & Mason Marks. war on drugs.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

JANUARY 5, 2022

The patent will be issued on January 11, 2022. This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

SpeedWeed

AUGUST 4, 2021

They presented case studies about patients who have had incredible success from their cannabis treatments. I want to be a part of the change that sees patients become able to access quality cannabis medicines and to change lives. I really couldn’t believe what I was hearing, but this was definitely the tipping point for me.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities. Group Psilocybin Facilitation (8 Hours).

Law 52

Law Programs Therapy Education 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

AUGUST 14, 2022

A 2022 rodent study found that cannabis significantly “increased functional coupling” in the RAS of male mice (but not female mice, oddly enough). If you don’t have access to lab reports, smell the weed before you buy it. The RAS is a sensitive piece of equipment – when it’s under or overstimulated, focusing can be difficult.

Terpenes 118

Terpenes Strains THC Oil 118

The Cannigma

DECEMBER 12, 2022

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. As activity increases in this network, we may be more self-critical and have rigid thought patterns.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 21, 2021

The school’s new location will be opening up in Q1 of 2022 to further ease the shortage and tension of much-needed healthcare workers. Ignite products are ecologically responsible and do not require additional wastewater treatment. Yet, more than half of the people in the least developed countries lack access to electricity.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

JANUARY 13, 2023

While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month. Ethan Russo details the historical use of cannabis for migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. Published on November 30, 2021.

Treatment 52

Treatment Clinical Trials Data Patients 52

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. Use harm reduction techniques (i.e.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52